Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

BMC Cancer

Nam Keun Kim⁴  Doyeun Oh⁵  Eo Jin Kim³  Sung Won Kwon²  So Young Chong⁵  Jisu Oh⁵  Jung O Kim⁴  Hyo Geun Jang⁴  Hye Mi Park¹  Jong Woo Kim²  Young Joo Jeon⁴ 

[1]Institute for Clinical Research, School of Medicine, CHA University, 351, Yatap-dong, Bundang-gu, Seongnam 463-712, South Korea

[2]Department of Surgery, School of Medicine, CHA University, Seongnam 463-712, South Korea

[3]Department of Medicine, College of Medicine, Chung-Ang University, Seoul 456-756, South Korea

[4]Department of Biomedical Science, College of Life Science, CHA University, Seongnam 463-712, South Korea

[5]Department of Internal Medicine, School of Medicine, CHA University, 351, Yatap-dong Bundang-gu Seongnam 463-712, South Korea

关键词: Metabolic syndrome;    Colorectal cancer;    Polymorphism;    3′-UTR;    VEGF;   

Others  :  1117993
DOI  :  10.1186/1471-2407-14-881

 received in 2014-08-18, accepted in 2014-11-14,  发布年份 2014

【 摘 要 】

Background

Polymorphisms in angiogenesis-related genes and metabolic syndrome (MetS) risk factors play important roles in cancer development. Moreover, recent studies have reported associations between a number of 3′-UTR polymorphisms and a variety of cancers. The aim of this study was to investigate the associations of three VEGF 3′-UTR polymorphisms (1451C > T [rs3025040], 1612G > A [rs10434], and 1725G > A [rs3025053]) and MetS with colorectal cancer (CRC) susceptibility in Koreans.

Methods

A total of 850 participants (450 CRC patients and 400 controls) were enrolled in the study. The genotyping of VEGF polymorphisms was performed by TaqMan allelic discrimination assays. Cancer risks of genetic variations and gene-environment interactions were assessed by adjusted odds ratios (AORs) and 95% confidence intervals (CIs) of multivariate logistic regression analyses.

Results

VEGF 1451C > T was significantly associated with rectal cancer risk (Dominant model; AOR =1.58; 95% CI = 1.09 - 2.28; p = 0.015) whereas VEGF 1725G > A correlated with MetS risk (Dominant model; AOR =1.61; 95% CI =1.06 - 2.46; p = 0.026). Of the gene-environment combined effects, the interaction of VEGF 1451C > T and MetS contributed to increased rectal cancer risk (AOR = 3.15; 95% CI = 1.74 - 5.70; p < .001) whereas the combination of VEGF 1725G > A and MetS was involved with elevated colon cancer risk (AOR = 2.68; 95% CI = 1.30 - 1.55; p =0.008).

Conclusions

Our results implicate that VEGF 1451C > T and 1725G > A may predispose to CRC susceptibility and the genetic contributions may be varied with the presence of MetS.

【 授权许可】

   
2014 Jeon et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
• [2]Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008, 2008:CD005390.
• [3]Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
• [4]Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
• [5]Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
• [6]Hansen TF, Jakobsen A: Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics 2011, 12:1681-1693.
• [7]Wang L, Liu W, Jiang W, Lin J, Jiang Y, Li B, Pang D: A miRNA binding site single-nucleotide polymorphism in the 3′-UTR region of the IL23R gene is associated with breast cancer. PLoS One 2012, 7:e49823.
• [8]Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M: The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 2013, 23:142-147.
• [9]Yang P, Tang R, Zhu J, Zou L, Wu R, Zhou H, Mao Y, Li R, Hua D, Wang W, Zhang H: A functional variant at miR-24 binding site in B7-H2 alters susceptibility to gastric cancer in a Chinese Han population. Mol Immunol 2013, 56:98-103.
• [10]Zhou L, Zhang X, Li Z, Zhou C, Li M, Tang X, Lu C, Li H, Yuan Q, Yang M: Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One 2013, 8:e64331.
• [11]Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
• [12]Giovannucci E: Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007, 86:s836-s842.
• [13]Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL: Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009, 15:5141-5148.
• [14]Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR: The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006, 107:28-36.
• [15]Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K: Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:385-391.
• [16]La Vecchia C, D’Avanzo B, Negri E, Franceschi S: History of selected diseases and the risk of colorectal cancer. Eur J Cancer 1991, 27:582-586.
• [17]Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC: Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997, 57:4787-4794.
• [18]Kono S, Honjo S, Todoroki I, Nishiwaki M, Hamada H, Nishikawa H, Koga H, Ogawa S, Nakagawa K: Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). Cancer Causes Control 1998, 9:441-446.
• [19]Will JC, Galuska DA, Vinicor F, Calle EE: Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998, 147:816-825.
• [20]Larsson SC, Orsini N, Wolk A: Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
• [21]Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F, Risk Factors and Life Expectancy Research Group: Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001, 10:937-941.
• [22]Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, Wang Y, Jin G, Ma H, Zhang M, Hu Z, Shen H: Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 2010, 31:1080-1086.
• [23]Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Hirata I, Arisawa T: Effect of polymorphisms in the 3′ untranslated region (3′-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol Carcinog 2009, 48:1030-1037.
• [24]Jang MJ, Jeon YJ, Kim JW, Cho YK, Lee SK, Hwang SG, Oh D, Kim NK: Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog 2013, 52:E60-E69.
• [25]Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002, 13:260-264.
• [26]Hansen TF, Spindler KL, Lorentzen KA, Olsen DA, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A: The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J Cancer Res Clin Oncol 2010, 136:751-758.
• [27]Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003, 106:468-471.
• [28]Antonacopoulou AG, Kottorou AE, Dimitrakopoulos FI, Triantafyllia V, Marousi S, Koutras A, Kalofonos HP: VEGF polymorphisms may be associated with susceptibility to colorectal cancer: a case–control study. Cancer Biomark 2011, 10:213-217.
• [29]Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, Loupakis F, Tonini G, Santini D, Magnani M: VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis 2009, 24:165-170.
• [30]Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
• [31]Crawford Y, Ferrara N: VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335:261-269.
• [32]Gurzu S, Jung J, Azamfirei L, Mezei T, Cîmpean AM, Szentirmay Z: The angiogenesis in colorectal carcinomas with and without lymph node metastases. Rom J Morphol Embryol 2008, 49:149-152.
• [33]Rodrigo JP, Cabanillas R, Chiara MD, García Pedrero J, Astudillo A, Suárez Nieto C: [Prognostic significance of angiogenesis in surgically treated supraglottic squamous cell carcinomas of the larynx]. Acta Otorrinolaringol Esp 2009, 60:272-277.
• [34]Kitadai Y: Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol 2010, 2010:468725.
• [35]Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997, 57:1043-1046.
• [36]Barozzi C, Ravaioli M, D’Errico A, Grazi GL, Poggioli G, Cavrini G, Mazziotti A, Grigioni WF: Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002, 94:647-657.
• [37]Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004, 17:197-203.
• [38]De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004, 100:270-278.
• [39]Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006, 94:1823-1832.
• [40]Giatromanolaki A, Stathopoulos GP, Tsiompanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999, 86:1421-1430.
• [41]Svagzdys S, Lesauskaite V, Pavalkis D, Nedzelskiene I, Pranys D, Tamelis A: Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer 2009, 9:95. BioMed Central Full Text
• [42]Heath VL, Bicknell R: Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009, 6:395-404.
• [43]Semenza GL: Hypoxia and cancer. Cancer Metastasis Rev 2007, 26:223-224.
• [44]Svagzdys S, Lesauskaite V, Pavalkis D, Nedzelskiene I, Pranys D, Tamelis A: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
• [45]Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
• [46]Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ: Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer 2012, 131:E636-E642.
• [47]Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012, 13:724-733.
• [48]Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, Giampieri R, Maccaroni E, Nicoletti S, Burattini L, Minardi D, Muzzonigro G, Montironi R, Cascinu S: VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer 2013, 108:1126-1132.
• [49]Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G: VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer 2013, 109:957-964.
• [50]Girgis CM, Cheng K, Scott CH, Gunton JE: Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends Endocrinol Metab 2012, 23:372-380.
• [51]Paul SA, Simons JW, Mabjeesh NJ: HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 2004, 200:20-30.